A composite skin substitute (graftskin) for surgical wounds. A clinical experience.
BACKGROUND
Bioengineered skin substitutes offer tissue replacement without requiring a donor site and might produce better healing.


OBJECTIVE
To evaluate the recipient's response to grafting a bioengineered skin equivalent onto acute surgical wounds.


METHODS
Graftskin, which is made of: 1) a bovine collagen matrix containing human fibroblasts, and 2) an overlying sheet of stratified human epithelium, was grafted onto the excision sites of 15 patients.


RESULTS
Blood and cell studies for toxicity were negative. Graftskin proved easy to handle, and a typical clinical appearance of the skin substitute during "take" was detected. Compared with expectations improved healing occurred. Twelve of 15 patients had initial clinical takes.


CONCLUSIONS
Graftskin was not clinically rejected and was not toxic. It often appeared to take and produced better than expected healing.
Eaglstein
W H
WH
Department of Dermatology, University of Miami School of Medicine, FL 33101, USA.
Iriondo
M
M
Laszlo
K
K
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D000906:Antibodies / Q000097:blood; D001798:Blood Proteins / Q000032:analysis; D002417:Cattle; D002455:Cell Division; D003094:Collagen / Q000276:immunology; D062109:Dermatologic Surgical Procedures; D005260:Female; D006680:HLA Antigens / Q000276:immunology; D006801:Humans; D008297:Male; D008875:Middle Aged; D012867:Skin / Q000503:physiopathology; D017768:Skin, Artificial; D013601:T-Lymphocytes / Q000166:cytology; D014945:Wound Healing / Q000276:immunology / Q000502:physiology
D000906:Antibodies; D001798:Blood Proteins; D006680:HLA Antigens; D003094:Collagen